[HTML][HTML] Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer
G Gonzalez-Avila, B Sommer… - Critical reviews in …, 2019 - Elsevier
Matrix metalloproteinases (MMPs) participate from the initial phases of cancer onset to the
settlement of a metastatic niche in a second organ. Their role in cancer progression is …
settlement of a metastatic niche in a second organ. Their role in cancer progression is …
[HTML][HTML] MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer
Dysregulation of microRNAs (miRNAs) is involved in the initiation and progression of
several human cancers, including breast cancer (BC), as strong evidence has been found …
several human cancers, including breast cancer (BC), as strong evidence has been found …
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
S Gholamin, SS Mitra, AH Feroze, J Liu… - Science translational …, 2017 - science.org
Morbidity and mortality associated with pediatric malignant primary brain tumors remain high
in the absence of effective therapies. Macrophage-mediated phagocytosis of tumor cells via …
in the absence of effective therapies. Macrophage-mediated phagocytosis of tumor cells via …
Dissecting tumor growth: the role of cancer stem cells in drug resistance and recurrence
B Aramini, V Masciale, G Grisendi, F Bertolini, M Maur… - Cancers, 2022 - mdpi.com
Simple Summary Cancer is one of the most debated problems all over the world. Cancer
stem cells are considered responsible of tumor initiation, metastasis, drug resistance, and …
stem cells are considered responsible of tumor initiation, metastasis, drug resistance, and …
The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets
SL Wood, M Pernemalm, PA Crosbie… - Cancer treatment …, 2014 - Elsevier
Non-small cell lung cancer (NSCLC) accounts for> 80% of lung cancer cases and currently
has an overall five-year survival rate of only 15%. Patients presenting with advanced stage …
has an overall five-year survival rate of only 15%. Patients presenting with advanced stage …
Targeting CXCL12/CXCR4 axis in tumor immunotherapy
Chemokines, which have chemotactic abilities, are comprised of a family of small cytokines
with 8-10 kilodaltons. Chemokines work in immune cells by trafficking and regulating cell …
with 8-10 kilodaltons. Chemokines work in immune cells by trafficking and regulating cell …
The strategies to cure cancer patients by eradicating cancer stem-like cells
Y Mai, J Su, C Yang, C Xia, L Fu - Molecular Cancer, 2023 - Springer
Cancer stem-like cells (CSCs), a subpopulation of cancer cells, possess remarkable
capability in proliferation, self-renewal, and differentiation. Their presence is recognized as a …
capability in proliferation, self-renewal, and differentiation. Their presence is recognized as a …
Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways
Lung cancer is the leading cause of cancer mortality worldwide. Despite advances in anti-
cancer therapies such as chemotherapy, radiotherapy and targeted therapies, five-year …
cancer therapies such as chemotherapy, radiotherapy and targeted therapies, five-year …
A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer
H Nechushtan, Y Hamamreh, S Nidal, M Gotfried… - The …, 2015 - academic.oup.com
Abstract Author Summary Background. Disulfiram, an alcohol aversion agent, has been in
use for> 50 years. Numerous authors have reported an anticancer effect of this drug in vitro …
use for> 50 years. Numerous authors have reported an anticancer effect of this drug in vitro …
Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer
H Willers, CG Azzoli, WL Santivasi, F Xia - The Cancer Journal, 2013 - journals.lww.com
In recent years, there have been multiple breakthroughs in our understanding of lung cancer
biology. Despite significant advances in molecular targeted therapies, DNA-damaging …
biology. Despite significant advances in molecular targeted therapies, DNA-damaging …